KPV

Four things to know · April 15, 2026

KPV overview

KPV · Nasal spray

Lysine-Proline-Valine

Nasal KPV delivers anti-inflammatory action directly to the sinus passages for chronic sinusitis and nasal inflammation.

6 studies cited

Noticed in days · Full benefit in weeks

Week 1

Typically reduced nasal congestion and sinus pressure.

Week 2-3

Commonly improved breathing and reduced sinus inflammation.

Week 4-6

Significant relief from chronic sinusitis symptoms is commonly reported.

Nasal KPV delivers anti-inflammatory action directly to the sinus passages for chronic sinusitis and nasal inflammation. Targets the source of sinus inflammation without systemic exposure.

DOSING

Nasal spray protocols

ProtocolDoseFrequency
Chronic sinusitis200-400mcg1-2x daily
Acute sinus inflammation400mcg2x daily for 1-2 weeks

Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.

What people report

Week 1

Typically reduced nasal congestion and sinus pressure.

Week 2-3

Commonly improved breathing and reduced sinus inflammation.

Week 4-6

Significant relief from chronic sinusitis symptoms is commonly reported.

What to know

  • Do not use if nasal passages are actively infected
  • Monitor for nasal irritation with prolonged use
  • Store in refrigerator after opening
  • Consult healthcare provider if using other nasal medications

Also available as

HOW IT WORKS

How KPV works

Most anti-inflammatory compounds work on the surface of cells. KPV is small enough to pass through the membrane and reach the nucleus, where it blocks NF-κB, one of the body's main inflammation switches. That inside-out approach is why it's being studied for conditions where inflammation is deep and persistent.

BEST FOR

Key benefits

  • Reduces inflammation from inside the cell, not just the surface
  • Antimicrobial action alongside the anti-inflammatory effect
  • No skin pigmentation changes (unlike the full hormone it comes from)
  • Particularly promising for gut and skin inflammation
REGULATORY STATUS

Regulatory status

Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review KPV on July 23, 2026, for potential addition to the 503A bulks list. The uses under review: wound healing and inflammatory conditions.

KEY RESEARCH · 6 PAPERS CITED

Dalmasso G et al.

Gastroenterology

2008

Read paper →

Kannengiesser K et al.

Inflammatory Bowel Diseases

2008

Read paper →

Xiao B et al.

Molecular Therapy

2017

Read paper →

Land SC

International Journal of Physiology, Pathophysiology and Pharmacology

2012

Read paper →

Viennois E et al.

Cellular and Molecular Gastroenterology and Hepatology

2016

Read paper →

Cutuli M et al.

Journal of Leukocyte Biology

2000

Read paper →

The Pep Dispatch

Follow the evidence on KPV as it evolves.

Subscribe to find out what.

Next dispatch · May 2026 · Honest frequency: a few times a month

For the people who want to feel better — not just look up symptoms.